Literature DB >> 33751319

Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.

Rachel A Pozzar1, Fangxin Hong2, Niya Xiong2, Jill E Stopfer2, Manan M Nayak2, Meghan Underhill-Blazey2,3.   

Abstract

In a sample of individuals with ovarian cancer, we aimed to (a) identify factors associated with the psychosocial impact of genetic counseling and multigene panel testing, (b) identify factors associated with cancer genetics knowledge, and (c) summarize patient-reported recommendations to improve the genetic counseling and multigene panel testing process. Eligible participants in this secondary analysis of quantitative and qualitative survey data were English-speaking adults with ovarian cancer. Psychosocial impact was assessed using the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Knowledge of cancer genetics was assessed using the KnowGene scale. Significant predictors of MICRA and KnowGene scores were identified using multiple regression. Open-ended survey item responses were analyzed using conventional content analysis. Eighty-seven participants met eligibility criteria. A positive genetic test result was associated with greater adverse psychosocial impact (B = 1.13, p = 0.002). Older age (B = - 0.07, p = 0.044) and being a member of a minority racial or ethnic group (B = - 3.075, p = 0.033) were associated with lower knowledge, while a personal history of at least one other type of cancer (B = 1.975, p = 0.015) was associated with higher knowledge. In open-ended item responses, participants wanted clinicians to assist with family communication, improve result disclosure, and enhance patient and family understanding of results. A subset of individuals with ovarian cancer who receive a positive genetic test result may be at risk for adverse psychosocial outcomes. Tailored cancer genetics education is necessary to promote the equitable uptake of targeted ovarian cancer treatment and risk-reducing therapies. Interventions to enhance patient-clinician communication in this setting are a research priority.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Genetic counseling; Genetic testing; Hereditary; Knowledge; Neoplastic syndromes; Ovarian neoplasms; Psychological distress

Mesh:

Year:  2021        PMID: 33751319     DOI: 10.1007/s10689-021-00240-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  39 in total

1.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.

Authors:  Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Authors:  Kathryn P Pennington; Tom Walsh; Maria I Harrell; Ming K Lee; Christopher C Pennil; Mara H Rendi; Anne Thornton; Barbara M Norquist; Silvia Casadei; Alexander S Nord; Kathy J Agnew; Colin C Pritchard; Sheena Scroggins; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

Review 3.  Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.

Authors:  Rossella Graffeo; Luca Livraghi; Olivia Pagani; Aron Goldhirsch; Ann H Partridge; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2016-10-12       Impact factor: 4.872

4.  Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.

Authors:  Johnathan M Lancaster; C Bethan Powell; Lee-May Chen; Debra L Richardson
Journal:  Gynecol Oncol       Date:  2014-09-17       Impact factor: 5.482

5.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

Review 6.  "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.

Authors:  Chrystelle Colas; Lisa Golmard; Antoine de Pauw; Sandrine M Caputo; Dominique Stoppa-Lyonnet
Journal:  Breast       Date:  2019-01-08       Impact factor: 4.380

7.  Frameshift mutation of Timm8a1 gene in mouse leads to an abnormal mitochondrial structure in the brain, correlating with hearing and memory impairment.

Authors:  Pingping Song; Yuqing Guan; Xia Chen; Chaochen Wu; An Qiao; Haishan Jiang; Qi Li; Yingwei Huang; Wei Huang; Miaojing Xu; Ouattara Niemtiah; Chao Yuan; Wei Li; Liang Zhou; Zhongju Xiao; Suyue Pan; Yafang Hu
Journal:  J Med Genet       Date:  2020-08-20       Impact factor: 6.318

8.  Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study.

Authors:  Michael J Hall; Linda J Patrick-Miller; Brian L Egleston; Susan M Domchek; Mary B Daly; Pamela Ganschow; Generosa Grana; Olufunmilayo I Olopade; Dominique Fetzer; Amanda Brandt; Rachelle Chambers; Dana F Clark; Andrea Forman; Rikki Gaber; Cassandra Gulden; Janice Horte; Jessica M Long; Terra Lucas; Shreshtha Madaan; Kristin Mattie; Danielle McKenna; Susan Montgomery; Sarah Nielsen; Jacquelyn Powers; Kim Rainey; Christina Rybak; Michelle Savage; Christina Seelaus; Jessica Stoll; Jill E Stopfer; Xinxin Shirley Yao; Angela R Bradbury
Journal:  JCO Precis Oncol       Date:  2018-12-18

9.  Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

Authors:  Xin Yang; Goska Leslie; Alicja Doroszuk; Sandra Schneider; Jamie Allen; Brennan Decker; Alison M Dunning; James Redman; James Scarth; Inga Plaskocinska; Craig Luccarini; Mitul Shah; Karen Pooley; Leila Dorling; Andrew Lee; Muriel A Adank; Julian Adlard; Kristiina Aittomäki; Irene L Andrulis; Peter Ang; Julian Barwell; Jonine L Bernstein; Kristie Bobolis; Åke Borg; Carl Blomqvist; Kathleen B M Claes; Patrick Concannon; Adeline Cuggia; Julie O Culver; Francesca Damiola; Antoine de Pauw; Orland Diez; Jill S Dolinsky; Susan M Domchek; Christoph Engel; D Gareth Evans; Florentia Fostira; Judy Garber; Lisa Golmard; Ellen L Goode; Stephen B Gruber; Eric Hahnen; Christopher Hake; Tuomas Heikkinen; Judith E Hurley; Ramunas Janavicius; Zdenek Kleibl; Petra Kleiblova; Irene Konstantopoulou; Anders Kvist; Holly Laduca; Ann S G Lee; Fabienne Lesueur; Eamonn R Maher; Arto Mannermaa; Siranoush Manoukian; Rachel McFarland; Wendy McKinnon; Alfons Meindl; Kelly Metcalfe; Nur Aishah Mohd Taib; Jukka Moilanen; Katherine L Nathanson; Susan Neuhausen; Pei Sze Ng; Tu Nguyen-Dumont; Sarah M Nielsen; Florian Obermair; Kenneth Offit; Olufunmilayo I Olopade; Laura Ottini; Judith Penkert; Katri Pylkäs; Paolo Radice; Susan J Ramus; Vilius Rudaitis; Lucy Side; Rachel Silva-Smith; Valentina Silvestri; Anne-Bine Skytte; Thomas Slavin; Jana Soukupova; Carlo Tondini; Alison H Trainer; Gary Unzeitig; Lydia Usha; Thomas van Overeem Hansen; James Whitworth; Marie Wood; Cheng Har Yip; Sook-Yee Yoon; Amal Yussuf; George Zogopoulos; David Goldgar; John L Hopper; Georgia Chenevix-Trench; Paul Pharoah; Sophia H L George; Judith Balmaña; Claude Houdayer; Paul James; Zaki El-Haffaf; Hans Ehrencrona; Marketa Janatova; Paolo Peterlongo; Heli Nevanlinna; Rita Schmutzler; Soo-Hwang Teo; Mark Robson; Tuya Pal; Fergus Couch; Jeffrey N Weitzel; Aaron Elliott; Melissa Southey; Robert Winqvist; Douglas F Easton; William D Foulkes; Antonis C Antoniou; Marc Tischkowitz
Journal:  J Clin Oncol       Date:  2019-12-16       Impact factor: 44.544

10.  Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.

Authors:  Valentina Vysotskaia; K Eerik Kaseniit; Leslie Bucheit; Kaylene Ready; Kristin Price; Katherine Johansen Taber
Journal:  Cancer       Date:  2019-11-04       Impact factor: 6.860

View more
  2 in total

1.  Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?

Authors:  Jeanna M McCuaig; Sarah E Ferguson; Danielle Vicus; Karen Ott; Tracy L Stockley; Raymond H Kim; Kelly A Metcalfe
Journal:  Hered Cancer Clin Pract       Date:  2022-04-13       Impact factor: 2.857

2.  Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings.

Authors:  Jude Emmanuel Cléophat; Michel Dorval; Zaki El Haffaf; Jocelyne Chiquette; Stephanie Collins; Benjamin Malo; Vincent Fradet; Yann Joly; Hermann Nabi
Journal:  BMC Med Genomics       Date:  2021-06-26       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.